MONDAY, April 8, 2024 (HealthDay News) — For patients with gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, cadonilimab plus chemotherapy is associated with improved overall survival and progression-free survival, according to a study presented at the annual meeting of the American Association for Cancer Research, held from April 5 to 10 in San Diego.
Jiafu Ji, M.D., Ph.D., from the Gastrointestinal Cancer Center at Peking University Cancer Hospital & Institute in Beijing, and colleagues conducted a randomized, placebo-controlled trial involving adults with untreated, unresectable, locally advanced, or metastatic G/GEJ adenocarcinoma, regardless of PD-L1 expression. Patients from 76 study centers were randomly assigned to cadonilimab plus chemotherapy or placebo plus chemotherapy (305 patients to each group), with a median follow-up of 18.69 months.
The researchers found median overall survival to be longer in the cadonilimab versus the placebo group (15.0 versus 10.8 months; hazard ratio, 0.62). At all prespecified combined positive score cutoffs, overall survival benefits were consistently observed, especially in patients with low PD-L1 expression. The cadonilimab group had longer progression-free survival (median, 7.0 versus 5.3 months; hazard ratio, 0.53). Grade ≥3 treatment-related adverse events occurred in 71.8 and 60.5 percent of patients who received cadonilimab and placebo, respectively; there were no new safety events reported.
“These findings may change the current practice of gastric cancer treatment,” Ji said in a statement. “Cadonilimab combined with chemotherapy could become a new standard of care in first-line treatment of gastric cancer, even for patients with low PD-L1 expression.”
The study was funded by Akeso Biopharma, the manufacturer of cadonilimab.
Copyright © 2024 HealthDay. All rights reserved.
